PDL BioPharma Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PDL BioPharma (PDLI) Reports Q2 Revenues Above Consensus
August 8, 2018 4:39 PM EDTPDL BioPharma (NASDAQ: PDLI) reported Q2 EPS of ($0.76), versus $0.06 reported last year. Revenue for the quarter came in at $46.6 million versus the consensus estimate of $44.66 million.
Total revenues of $46.6 million.GAAP net loss attributable to PDL\'s shareholders of $112.3 million or $(0.76) per share.GAAP net loss includes a one-time $133.3 million, net of tax, non-cash accounting charge related to the impairment of an intangible asset from Noden Pharma DAC, due to the increased probability of a... More